How many drugs treat Chronic bronchitis?

Drug Landscape tracks 8 marketed treatments for Chronic bronchitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic bronchitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Breo Ellipta	VILANTEROL	Glaxo Grp Ltd	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2013-01-01
Incruse Ellipta	UMECLIDINIUM	Glaxo Grp England	Anticholinergic	Muscarinic acetylcholine receptor M4	2013-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	Corticosteroid	Glucocorticoid receptor	2007-01-01
Brovana	ARFORMOTEROL	Lupin	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2006-01-01
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
UMEC	UMEC	Glaxo Grp England		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Incruse	Incruse	Fundacio Privada Mon Clinic Barcelona		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Brovana	Brovana	Wake Forest University Health Sciences		Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-3 adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Glaxo Grp England · 2 drugs in Chronic bronchitis
· 2 drugs in Chronic bronchitis
Fundacio Privada Mon Clinic Barcelona · 1 drug in Chronic bronchitis
Glaxo Grp Ltd · 1 drug in Chronic bronchitis
Haleon Us Holdings · 1 drug in Chronic bronchitis
Lupin · 1 drug in Chronic bronchitis
Wake Forest University Health Sciences · 1 drug in Chronic bronchitis
Boehringer Ingelheim · 1 drug in Chronic bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic bronchitis:

Cite this brief

Drug Landscape (2026). Chronic bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-bronchitis. Accessed 2026-06-10.

Chronic bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing